Publications Archive - KalVista Pharmaceuticals

Showing 2 out of 2

Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation

Clermont AC, Murugesan N, Edwards HJ, Lee DK, Bayliss NP, Duckworth EJ, Pethen SJ, Hampton SL, Gailani D, Feener EP

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat

Cohn DM, Aygören-Pürsün E, Bernstein JA, Farkas H, Lumry WR, Maurer M, Zanichelli A, Iverson M, Hao J, Smith MD, Yea CM, Audhya PK, Riedl MA

2023 Clinical and Translation Allergy

About

Science

Pipeline

Careers

Contact